Eurofins Scientific

A decent end to FY24: investors jittery with biopharma headwinds

31/01/25 -"During FY24, Eurofins’ revenue was in line with market expectations, but the EPS and FCF outperformed. The initial knee-jerk reaction was attributable to continued weakness in the Biopharma ..."

PDF page sample
Pages
47
Language
English
Published on
31/01/25
Download
You may also be interested by these reports :
06/02/26
We adopt a more cautious stance on Experian, as AI-related developments drive sector-wide compression across legacy data and analytics companies, ...
04/02/26
Q4 2025 was a solid quarter, with organic growth across all regions driven by price increases in security services and the development of technology ...
29/01/26
Eurofins Scientific’s 2025 results were in line with the Visible Alpha consensus but slightly below our expectations. Organic growth was marginally ...
27/01/26
After the pre-close call for FY25 that we had with management, we again adjust our topline growth forecasts for the group, with an impact on EPS. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO